Umoja wa Ulaya - Kiitaliano - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Umoja wa Ulaya - Kiitaliano - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosoppressori - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

vifor fresenius medical care renal pharma ltd. - avacopanum - capsule rigide - avacopanum 10 mg, macrogolglyceroli hydroxystearas 245 mg, macrogolum 4000, kapselhülle: e 172 (rubrum), e 172 (flavum), e 171, gelatina, polysorbatum 80, drucktinte: e 172 (nigrum), pro capsula. - behandlung erwachsener patienten mit schwerer aktiver vaskulitis (granulomatose mit polyangiitis (gpa) oder mikroskopischer polyangiitis (mpa)) - synthetika

Umoja wa Ulaya - Kiitaliano - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - neoplasie al seno - terapia endocrina - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Italia - Kiitaliano - AIFA (Agenzia Italiana del Farmaco)

intermedical srl - mepivacaina, associazioni - mepivacaina, associazioni

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - capivasertibum - compresse rivestite con film - capivasertibum 160 mg, cellulosum microcristallinum, calcii hydrogenophosphas, carmellosum natricum conexum corresp. natrium max. 1.82 mg, magnesii stearas, Überzug: hypromellosum, copovidonum k 28, macrogolum 3350, polydextrosum, triglycerida media, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - carcinoma della mammella - synthetika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - capivasertibum - compresse rivestite con film - capivasertibum 200 mg, cellulosum microcristallinum, calcii hydrogenophosphas, carmellosum natricum conexum corresp. natrium max. 2.28 mg, magnesii stearas, Überzug: hypromellosum, copovidonum k 28, macrogolum 3350, polydextrosum, triglycerida media, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - carcinoma della mammella - synthetika

Italia - Kiitaliano - AIFA (Agenzia Italiana del Farmaco)

italfarmaco s.p.a. - itraconazolo - itraconazolo

Umoja wa Ulaya - Kiitaliano - EMA (European Medicines Agency)

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirali per uso sistemico - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

Italia - Kiitaliano - AIFA (Agenzia Italiana del Farmaco)

orpha-devel handels und vertriebs gmbh - vasopressina - vasopressina